• share
• favorite_border

The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded four Innovative Grants; three Career Development Awards; one Pathway to Leadership Grant; and one Fellowship Award to outstanding researchers for their innovative research proposals which have the potential to lead to medical breakthroughs in the treatment of pancreatic cancer.

• share
• favorite_border

Titia de Lange, Ph.D., will receive the 50th annual American Association for Cancer Research G.H.A. Clowes Memorial Award for outstanding contributions to cancer research through the elucidation of telomere biology. The award will be presented at the AACR 101st Annual Meeting 2010. De Lange is the Leon Hess professor and associate director of the Anderson Cancer Center at The Rockefeller University, New York, and an American Cancer Society research professor.

• share
• favorite_border

The world’s leading researchers whose efforts have significantly contributed to progress in the fight against cancer will be recognized by the American Association for Cancer Research at its 101st Annual Meeting 2010, held April 17-21, 2010, at the Walter E. Washington Convention Center.

• share
• favorite_border

Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT), will receive the fourth annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 101st Annual Meeting 2010.

• share
• favorite_border

Five innovative young investigators have been selected to present their work at the Future Leaders in Translational Cancer Research Special Symposium during the AACR 101st Annual Meeting 2010 in Washington, D.C., April 17-21. Their work spans the fields of carcinogenesis, cellular biology, radiation biology, experimental therapeutics, molecular biology, immunology, bioengineering, and clinical investigations. Senior scientists will share the stage, providing context for the talks and elucidating the continuum of achievement within these research areas.

• share
• favorite_border

The American Association for Cancer Research and the Kirk A. and Dorothy P. Landon Foundation will present three INNOVATOR Awards at the AACR 101st Annual Meeting 2010, held April 17-21, in Washington, D.C.

• share
• favorite_border

Janet D. Rowley, M.D., will receive the seventh annual American Association for Cancer Research Award for Lifetime Achievement in Cancer Research at the AACR 101st Annual Meeting 2010.

• share
• favorite_border

The American Association for Cancer Research will honor three visionary leaders for their distinguished public service. John E. Niederhuber, M.D., director of the National Cancer Institute (NCI); Julie M. Fleshman, J.D., M.B.A., president and chief executive officer of the Pancreatic Cancer Action Network; and Jon M. Huntsman, founder of the Huntsman Corporation, were chosen by the AACR’s Board of Directors in recognition of their commitment and dedication to the fight against cancer.

• share
• favorite_border

Dana-Farber/Harvard Cancer Center Thoracic Oncology Research Team Receives the AACR’s Fourth Annual Team Science Award

• share
• favorite_border

The AACR would like to congratulate its newest grantees at the AACR 101st Annual Meeting 2010, held April 17-21.

• share
• favorite_border

The American Association for Cancer Research (AACR) is offering teleconference lines for media interested in participating in the press briefings scheduled during its AACR 101st Annual Meeting 2010, April 17-21 in Washington, D.C. Following the briefings, the phone lines will be opened for question and answer sessions.

• share
• favorite_border

The members of the American Association for Cancer Research have elected Judy E. Garber, M.D., M.P.H., as their president-elect. Garber is the director of the Cancer Risk and Prevention Program at the Dana-Farber Cancer Institute, associate professor of Medicine at Harvard Medical School, and associate physician of medicine and attending physician of medical service at Brigham and Women’s Hospital, Boston, Mass.

• share
• favorite_border

• Analgesic use may decrease postmenopausal estrogen levels. • Possible inverse association between analgesic use and cancer risk.

• share
• favorite_border

1) Treatment resulted in signs of cell death; 2) Lymphoma tends to respond poorly to chemotherapy.

• share
• favorite_border

1) Iraqi women commonly have late stage and more aggressive types of breast cancer; 2) Approximately one-third diagnosed were 40 to 49 years of age; 3) About 16 percent of the women reported a family history of breast cancer.

• share
• favorite_border

1) Ultrasound guidance may prevent damage to healthy tissues; 2) Malignant tumors responded better to moderate heat; 3) Benign tumors responded to heat therapy.

• share
• favorite_border

1) Many people are unaware of obesity’s effect on cancer risk; 2) Effect is stronger in men than in women.

• share
• favorite_border

1)Therapeutic activity demonstrated in vitro and in vivo; 2) Virus’ effect is selective for prostate cancer; not normal tissue; 3) Safety and efficacy shown in early-stage prostate cancer.

• share
• favorite_border

1) This is the only major cancer conference to take place in the Middle East; 2) Researchers from more than 27 countries will attend; 3) Conference provides data on geographical variations in cancer instances.

• share
• favorite_border

1) Bitter melon extract inhibited breast cancer cell proliferation; 2) Extract may be used as a dietary supplement to induce cancer cell death.

• share
• favorite_border

1) Arsenic acts as a co-carcinogen by inducing Hedgehog activity; 2) Arsenic alters Hedgehog signaling and targets a transcription factor; 3) Exposure functions as a carcinogen for lung, skin and bladder cancers.

• share
• favorite_border

1) Less than a quarter of one percent of women took tamoxifen in 2000 and 2005 to prevent breast cancer; 2) Further research is recommended to explore explanations for the drug’s low use.

• share
• favorite_border

1) Cigarette smokers may have heightened cancer awareness, making them more open to vaccination for cancer prevention; 2) Physical activity also associated with greater vaccine acceptance; 3) Users of complementary and alternative therapy are less accepting of vaccine.

• share
• favorite_border

1) Increased sugar intake may stimulate tumor growth through effects of insulin; 2) Pancreatic cancer rates increased nearly twofold over the past several decades; 3) Drinking two or more soft drinks a week led to an 87 percent increased risk.

• share
• favorite_border

Premier international meeting to highlight breakthroughs in cancer treatment, emerging therapies and molecular science.

• share
• favorite_border

The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Zeshaan A. Rasheed, M.D., Ph.D., the 2010 Pancreatic Cancer Action Network-AACR Pathway to Leadership Grant. This grant, totaling $600,000 over five years, will support Rasheed’s efforts to examine the relevance of cancer stem cells in pancreatic adenocarcinoma.

• share
• favorite_border

The American Association for Cancer Research and the International Association for the Study of Lung Cancer (IASLC) honored Paul A. Bunn Jr., M.D., for his leadership in lung cancer research at the first Molecular Origins of Lung Cancer conference this week. The conference, held from Jan. 11-14, 2010, drew more than 300 people from around the world. Bunn is professor of medicine and the James Dudley chair in cancer research at the University of Colorado, Denver.

• share
• favorite_border

1) Gefitinib treatment ineffective as first-line therapy; 2) Limited treatment options are available in this patient group; 3) Disease stabilization is observed in many cases.

• share
• favorite_border

1) ALK gene rearrangements occur in about 3 to 5 percent of cases; 2) Lung cancer is recognized as different diseases at a molecular level; 3) Results may speed ALK-inhibitor approval in ALK-positive lung cancer.

• share
• favorite_border

1) ASA404 effective and well tolerated, regardless of histology; 2) Possible use for targeted therapy for this patient group.

• share
• favorite_border

1) Smokers tolerated higher doses of erlotinib; 2) Erlotinib is used as a second-line therapy; 3) Side effects included rash and diarrhea.

• share
• favorite_border

1) Currently, high rate of false positives occur with X-ray examination; 2) New blood test provided 88 percent sensitivity, 79 percent specificity.

• share
• favorite_border

1) Chemoresistance to first-line therapy affects about 6,500 patients a year; 2) Only two first-line chemotherapies are currently standard treatment.

• share
• favorite_border

1) 93-gene signature developed that correlates with EGFR mutation; 2) Testing also being conducted in head and neck, colorectal and breast cancers; 3) Clinical results of the BATTLE trial to be presented later this year.

• share
• favorite_border

1) Researchers divided tumors into three types of growth patterns; 2) Independent predictive value for survival found in these patients; 3) This is useful in patients undergoing operations.

• share
• favorite_border

1) Green tea reduced the risk of lung cancer in smokers; 2) Benefit was also seen in non-smokers.

• share
• favorite_border

1) Survival represents a victory, but also a challenge; 2) Survivors more likely to have diabetes, high cholesterol, high blood pressure; 3) No increased risk of obesity.

• share
• favorite_border

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

• share
• favorite_border

1) Anti-aromatase phytochemicals detected in pomegranates; 2) Urolithin B inhibited estrogen production and reduced cancer spread; 3) Additional research is needed to evaluate potential risks and benefits.

• share
• favorite_border

1) Cancer increased 30 percent less in patients on the NSAID treatment; 2) This effect was seen in patients with severe disease.

• share
• favorite_border

In partnership with the International Association for the Study of Lung Cancer, the American Association for Cancer Research will host the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, which will bring together leaders from all over the world who share the goal of eradicating this form of cancer.

• share
• favorite_border

Dennis Slamon, M.D., Ph.D., director of clinical/translational research for the Revlon/University of California, Los Angeles (UCLA) Women’s Cancer Research Program at UCLA’s Jonsson Comprehensive Cancer Center, will present updated results of his groundbreaking work with trastuzumab, currently sold as Herceptin by Genentech-Roche.

• share
• favorite_border

As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions.

• share
• favorite_border

As scientists and clinicians continue to uncover new information about breast cancer, the landscape of acceptable treatment and management continues to shift.

• share
• favorite_border

1) Results are not explained by lack of access to care or more advanced stage; 2) Chemotherapy, hormonal therapy adherence was similar among groups.

• share
• favorite_border

1) Anti-estrogen therapy significantly decreased the risk of lung cancer death; 2) Results support the role of estrogens in lung cancer management.

• share
• favorite_border

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

• share
• favorite_border

1) Fewer advanced cancers detected with MRI plus mammography; 2) Early detection meant smaller breast cancer size, less lymph node spread; 3) Overall, high-risk women with gene mutations benefited from MRI screening.

• share
• favorite_border

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

• share
• favorite_border

1) Obesity leads to late diagnosis of breast cancer; 2) Obese patients have poorer breast cancer survival; 3) Adjuvant treatment is less effective in patients with a higher BMI.